Taxane-induced peripheral neuropathy and health-related quality of life in postoperative breast cancer patients undergoing adjuvant chemotherapy: N-SAS BC 02, a randomized clinical trial

Shimozuma, Kojiro; Ohashi, Yasuo; Takeuchi, Ayano; Aranishi, Toshihiko; Morita, Satoshi; Kuroi, Katsumasa; Ohsumi, Shozo; Makino, Haruhiko; Katsumata, Noriyuki; Kuranami, Masaru; Suemasu, Kimito; Watanabe, Tôru; Hausheer, Frederick H.

doi:10.1007/s00520-012-1492-x

Cited by 83 publications

(55 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In view of the importance of Docetaxel in the adjuvant and neoadjuvant therapies for breast cancer treatment, as well as its ole in the prevention of relapse, Docetaxel-induce peripheral neuropathy lacks further studies to explore appropriate management forms, without causing losses for the treatment but being able to maintain the patients' quality of life. (22,23) The limits of this study were mainly related to the small sample size, as the population is very specific, despite including the entire population of women who complied with the inclusion criteria in the study context, in view of the established data collection period. Thus, new studies are needed with larger samples.…”

Section: Discussionmentioning

confidence: 99%

Indução da dor pelo quimioterápico docetaxel em mulheres com câncer de mama

et al. 2016

View full text Add to dashboard Cite

Resumo Objetivo Descrever a frequência, características, localização, intensidade da dor em pacientes com câncer de mama em uso do quimioterápico Docetaxel. Métodos Estudo longitudinal realizado com 17 mulheres com câncer de mama em tratamento com Docetaxel. As pacientes foram avaliadas durante três ciclos da quimioterapia quanto à dor, utilizando-se os instrumentos Questionário McGill de Dor (Br-MPQ) e Brief Pain Inventory (BPI). Utilizou-se a correlação de Spearman e o teste de Mann-Whitney. Resultados Houve aumento na média da dor em todas as variáveis do BPI. Quando comparados os valores do Pain Rating Index (PRI) total foram verificados respectivamente 0,20; 0,33 e 0,24 na primeira, segunda e terceira avaliações, sendo encontrada correlação entre a intensidade da dor e a interferência em todas as atividades do cotidiano no BPI na segunda avaliação. Conclusão Houve aumento na ocorrência da dor, comprometendo as atividades diárias de vida das mulheres participantes.

show abstract

Section: Discussionmentioning

confidence: 99%

Indução da dor pelo quimioterápico docetaxel em mulheres com câncer de mama

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Taxane is known as one of the standard first-line treatments for metastatic breast cancer; however, patients often suffer adverse events such as hair loss, peripheral nerve disorders, and/or edema; thus, such a reduction in quality of life (QOL) becomes a problem [1][2][3] . Moreover, all patients need to be treated in a healthcare facility because taxane is given as an injection.…”

Section: Introductionmentioning

confidence: 99%

The Impact of Treatment Preferences in Second-Line Chemotherapy on the Prognosis of HER2-Negative Metastatic Breast Cancer

Mukai

Hagiwara²,

Imi³

et al. 2017

Oncology

View full text Add to dashboard Cite

Objective: We assessed the impact of treatment preferences in second-line chemotherapy on breast cancer prognosis using the SELECT BC study. Methods: The SELECT BC study was performed in patients with HER2-negative metastatic breast cancer treated with initial chemotherapy. From these patients, 618 were assigned to 2 groups (S-1 group, 309; taxane group, 309). The S-1 and taxane groups were each subdivided into 3 groups: crossover group, protocol-recommended group, and other group, and the analysis of overall survival (OS) was performed using Cox regression with inverse probability weighting, to adjust for postrandomization confounding. Results: In the taxane group, the OS of the crossover group (39.6 months) was better than that of the protocol-recommended group (35.7 months) and the other chemotherapy group (36.9 months) (vs. the protocol-recommended group, HR 0.72 [95% CI 0.52-0.98], p = 0.037; vs. the other chemotherapy group, HR 0.71 [95% CI 0.43-1.18], p = 0.183). In the S-1 group, there was no statistically significant difference in OS between the 3 groups. Conclusion: The study of the combination of first-line chemotherapy and second-line chemotherapy showed that S-1 might be recommended as a second-line chemotherapy in patients in whom taxane was the primary chemotherapy.

show abstract

“…through the CYP2C8 enzyme system suggest that variations in the CYP2C8 genotype may increase the risk of peripheral neuropathy via the attenuation of paclitaxel metabolism [11,12]. With a greater exposure to paclitaxel, severe forms of paclitaxel-induced peripheral neuropathy may be induced due to axon degeneration and lead to the persistence of the neurotoxicity [13][14][15][16]. A genome-wide association study provided evidence suggesting that genetic variations in the ephrin type A receptor (EPHA) genes are strongly associated with paclitaxel-induced peripheral neuropathy [17].…”

Section: Introductionmentioning

confidence: 99%

The genetic variants underlying breast cancer treatment-induced chronic and late toxicities: A systematic review

Ng¹,

Chan²,

Khor³

et al. 2014

Cancer Treatment Reviews

View full text Add to dashboard Cite

Taxane-induced peripheral neuropathy and health-related quality of life in postoperative breast cancer patients undergoing adjuvant chemotherapy: N-SAS BC 02, a randomized clinical trial

Abstract: Patient-reported CIPN was significantly more severe with single-agent adjuvant taxane compared to AC followed by taxane treatment; however, the HRQOL findings support that single-agent taxane treatment is tolerable.

Cited by 83 publications

References 25 publications

Indução da dor pelo quimioterápico docetaxel em mulheres com câncer de mama

Indução da dor pelo quimioterápico docetaxel em mulheres com câncer de mama

The Impact of Treatment Preferences in Second-Line Chemotherapy on the Prognosis of HER2-Negative Metastatic Breast Cancer

The genetic variants underlying breast cancer treatment-induced chronic and late toxicities: A systematic review

Contact Info

Product

Resources

About